Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.

Literature DB >> 23568163

P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.

Sasmit Sarangi¹, Ambarish Pandey, Anne-Laure Papa, Poulomi Sengupta, Jawahar Kopparam, Ushashi Dadwal, Sudipta Basu, Shiladitya Sengupta.

Abstract

Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has not been studied. In this study, we characterize the expression of P2Y12 receptor in breast cancer cell lines and evaluate its role in enhancing the cytotoxic effects of cisplatin. We observed a significant upregulation in P2Y12 expression in 4T1 breast cancer cell line with cisplatin treatment. Co-administration of P2Y12 inhibitor with cisplatin resulted in significantly higher cytotoxic response in 4T1 cancer cell line. This was mediated by HIF1α-dependent upregulation of cellular apoptotic pathways. These findings identify P2Y12 receptor as a potential target to enhance antitumor efficacy of chemotherapeutic agents like cisplatin.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 2013 PMID： 23568163 DOI： 10.1007/s12032-013-0567-y

Source DB: PubMed Journal: Med Oncol ISSN： 1357-0560 Impact factor: 3.064

22 in total

Review 1. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

Authors: Maria P Abbracchio; Geoffrey Burnstock; Jean-Marie Boeynaems; Eric A Barnard; José L Boyer; Charles Kennedy; Gillian E Knight; Marta Fumagalli; Christian Gachet; Kenneth A Jacobson; Gary A Weisman
Journal: Pharmacol Rev Date: 2006-09 Impact factor: 25.468

2. Atypical PKCzeta is involved in RhoA-dependent mitogenic signaling by the P2Y(12) receptor in C6 cells.

Authors: Kristof Van Kolen; Herman Slegers
Journal: FEBS J Date: 2006-04 Impact factor: 5.542

Review 3. The platelet contribution to cancer progression.

Authors: N M Bambace; C E Holmes
Journal: J Thromb Haemost Date: 2011-02 Impact factor: 5.824

4. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy.

Authors: Kevin S Choe; David Correa; Ashesh B Jani; Stanley L Liauw
Journal: Cancer Date: 2010-04-01 Impact factor: 6.860

Review 5. Triple negative breast cancer: unmet medical needs.

Authors: Sumanta Kumar Pal; Barrett H Childs; Mark Pegram
Journal: Breast Cancer Res Treat Date: 2010-12-15 Impact factor: 4.872

Review 6. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

Authors: Nadine Rohwer; Thorsten Cramer
Journal: Drug Resist Updat Date: 2011-04-03 Impact factor: 18.500

7. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients.

Authors: Hendrik J Agteresch; Sjaak A Burgers; Ate van der Gaast; J H Paul Wilson; Pieter C Dagnelie
Journal: Anticancer Drugs Date: 2003-09 Impact factor: 2.248

8. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.

Authors: E Rapaport; J Fontaine
Journal: Proc Natl Acad Sci U S A Date: 1989-03 Impact factor: 11.205

Review 9. Targeting HIF-1 for cancer therapy.

Authors: Gregg L Semenza
Journal: Nat Rev Cancer Date: 2003-10 Impact factor: 60.716

Review 10. Purines, purinergic receptors, and cancer.

Authors: Francesco Di Virgilio
Journal: Cancer Res Date: 2012-10-22 Impact factor: 12.701

10 in total

1. Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Authors: Ramindhu Galgamuwa; Kristine Hardy; Jane E Dahlstrom; Anneke C Blackburn; Elize Wium; Melissa Rooke; Jean Y Cappello; Padmaja Tummala; Hardip R Patel; Aaron Chuah; Luyang Tian; Linda McMorrow; Philip G Board; Angelo Theodoratos
Journal: J Am Soc Nephrol Date: 2016-03-09 Impact factor: 10.121

Review 2. The Function and Regulation of Platelet P2Y12 Receptor.

Authors: Xiaohua Li; Guoxing Zhang; Xia Cao
Journal: Cardiovasc Drugs Ther Date: 2021-07-28 Impact factor: 3.727

Review 3. P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Authors: Lucas T Woods; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Gary A Weisman
Journal: Biochem Pharmacol Date: 2021-01-04 Impact factor: 5.858

Review 4. Important roles of P2Y receptors in the inflammation and cancer of digestive system.

Authors: Han-Xing Wan; Jian-Hong Hu; Rei Xie; Shi-Ming Yang; Hui Dong
Journal: Oncotarget Date: 2016-05-10

5. Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.

Authors: Agnieszka Denslow; Marta Świtalska; Joanna Jarosz; Diana Papiernik; Kseniia Porshneva; Marcin Nowak; Joanna Wietrzyk
Journal: PLoS One Date: 2017-12-05 Impact factor: 3.240

Review 6. Antithrombotic Agents and Cancer.

Authors: Annalisa Bruno; Melania Dovizio; Stefania Tacconelli; Annalisa Contursi; Patrizia Ballerini; Paola Patrignani
Journal: Cancers (Basel) Date: 2018-07-31 Impact factor: 6.639

P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.

Review 1. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

2. Atypical PKCzeta is involved in RhoA-dependent mitogenic signaling by the P2Y(12) receptor in C6 cells.

Review 3. The platelet contribution to cancer progression.

4. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy.

Review 5. Triple negative breast cancer: unmet medical needs.

Review 6. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

7. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients.

8. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.

Review 9. Targeting HIF-1 for cancer therapy.

Review 10. Purines, purinergic receptors, and cancer.

1. Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Review 2. The Function and Regulation of Platelet P2Y12 Receptor.

Review 3. P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Review 4. Important roles of P2Y receptors in the inflammation and cancer of digestive system.

5. Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.

Review 6. Antithrombotic Agents and Cancer.

Review 7. P2Y₁₂ Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment.

Review 8. Emerging roles of purinergic signaling in anti-cancer therapy resistance.

Review 9. P2Y₁₂ Receptors in Tumorigenesis and Metastasis.

Review 10. P2Y₁₂ Inhibition beyond Thrombosis: Effects on Inflammation.

P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.

Review 1. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy.

2. Atypical PKCzeta is involved in RhoA-dependent mitogenic signaling by the P2Y(12) receptor in C6 cells.

Review 3. The platelet contribution to cancer progression.

4. The use of anticoagulants improves biochemical control of localized prostate cancer treated with radiotherapy.

Review 5. Triple negative breast cancer: unmet medical needs.

Review 6. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.

7. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients.

8. Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.

Review 9. Targeting HIF-1 for cancer therapy.

Review 10. Purines, purinergic receptors, and cancer.

1. Dichloroacetate Prevents Cisplatin-Induced Nephrotoxicity without Compromising Cisplatin Anticancer Properties.

Review 2. The Function and Regulation of Platelet P2Y12 Receptor.

Review 3. P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications.

Review 4. Important roles of P2Y receptors in the inflammation and cancer of digestive system.

5. Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.

Review 6. Antithrombotic Agents and Cancer.

Review 7. P2Y12 Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment.

Review 8. Emerging roles of purinergic signaling in anti-cancer therapy resistance.

Review 9. P2Y12 Receptors in Tumorigenesis and Metastasis.

Review 10. P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation.

Review 7. P2Y₁₂ Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment.

Review 9. P2Y₁₂ Receptors in Tumorigenesis and Metastasis.

Review 10. P2Y₁₂ Inhibition beyond Thrombosis: Effects on Inflammation.